Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Status:
Recruiting
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
A non randomized, unblinded, open label phase 2 study to investigate the efficacy of
pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with
PD-L1 genetic alterations